X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs LUPIN LTD - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. LUPIN LTD FRESENIUS KABI ONCO./
LUPIN LTD
 
P/E (TTM) x 22.1 29.5 74.9% View Chart
P/BV x 3.1 3.1 100.8% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   LUPIN LTD
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
LUPIN LTD
Mar-18
FRESENIUS KABI ONCO./
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1761,465 12.0%   
Low Rs79727 10.8%   
Sales per share (Unadj.) Rs37.7349.6 10.8%  
Earnings per share (Unadj.) Rs5.15.6 91.6%  
Cash flow per share (Unadj.) Rs6.729.6 22.7%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs42.5300.3 14.2%  
Shares outstanding (eoy) m158.23452.08 35.0%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.43.1 107.7%   
Avg P/E ratio x25.0197.2 12.7%  
P/CF ratio (eoy) x18.937.1 51.1%  
Price / Book Value ratio x3.03.6 82.0%  
Dividend payout %090.0 0.0%   
Avg Mkt Cap Rs m20,135495,502 4.1%   
No. of employees `0001.217.0 6.8%   
Total wages/salary Rs m70328,647 2.5%   
Avg. sales/employee Rs Th5,176.29,273.6 55.8%   
Avg. wages/employee Rs Th610.41,681.0 36.3%   
Avg. net profit/employee Rs Th699.6147.4 474.5%   
INCOME DATA
Net Sales Rs m5,963158,042 3.8%  
Other income Rs m181,504 1.2%   
Total revenues Rs m5,981159,545 3.7%   
Gross profit Rs m1,43031,475 4.5%  
Depreciation Rs m25810,859 2.4%   
Interest Rs m-262,044 -1.3%   
Profit before tax Rs m1,21620,076 6.1%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m-68-14,644 0.5%   
Tax Rs m3422,885 11.9%   
Profit after tax Rs m8062,513 32.1%  
Gross profit margin %24.019.9 120.4%  
Effective tax rate %28.114.4 195.8%   
Net profit margin %13.51.6 850.1%  
BALANCE SHEET DATA
Current assets Rs m5,102122,095 4.2%   
Current liabilities Rs m2,38550,956 4.7%   
Net working cap to sales %45.645.0 101.2%  
Current ratio x2.12.4 89.3%  
Inventory Days Days15085 177.4%  
Debtors Days Days113120 94.5%  
Net fixed assets Rs m5,148129,876 4.0%   
Share capital Rs m158904 17.5%   
"Free" reserves Rs m6,556134,866 4.9%   
Net worth Rs m6,732135,771 5.0%   
Long term debt Rs m95264,245 1.5%   
Total assets Rs m10,388263,054 3.9%  
Interest coverage x-45.810.8 -422.9%   
Debt to equity ratio x0.10.5 29.9%  
Sales to assets ratio x0.60.6 95.5%   
Return on assets %7.51.7 433.5%  
Return on equity %12.01.9 646.9%  
Return on capital %14.63.7 392.5%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29853,141 10.0%   
Fx outflow Rs m1,77219,335 9.2%   
Net fx Rs m3,52533,807 10.4%   
CASH FLOW
From Operations Rs m1,27417,512 7.3%  
From Investments Rs m-1,204-14,073 8.6%  
From Financial Activity Rs m-196-14,921 1.3%  
Net Cashflow Rs m-126-11,482 1.1%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 81.0 0.2 40,500.0%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 9.6 31.9 30.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.1 90.1%  
Shareholders   42,599 98,259 43.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  WYETH LTD  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ORCHID PHARMA LTD COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS